Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 43

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 43
---
 or purchase period under the Enfusion ESPP will commence after the date of the Merger Agreement, (b) no new participants
will be permitted into the Enfusion ESPP after the date of the Merger

23

Agreement, (c) the existing participants in the Enfusion ESPP may not increase their elections with respect to the offering or purchase periods in effect on the date of the Merger Agreement,
(d) the exercise date for any offering or purchase period in effect as of the date of the Merger Agreement will be the earlier of the original exercise date for such offering and the date that is 60 days after the date of the Merger Agreement
(the “”), (e) each participant’s accumulated contributions under the Enfusion ESPP will be used to purchase shares of Enfusion Common Stock in accordance with the terms of the Enfusion ESPP as of the Final
Exercise Date, and (f) the Enfusion ESPP will terminate on the date immediately prior to the date on which the Effective Time occurs.

Listing of Clearwater Common Stock; Delisting of Enfusion Common Stock(see page 114)

It is a condition to the completion of the
Transactions that the shares of Clearwater Common Stock to be issued to Enfusion Stockholders in the Transactions be approved for listing on New York Stock Exchange, subject to official notice of issuance. As a result of the Transactions, shares of
Enfusion Common Stock will cease to be listed on the New York Stock Exchange.

Appraisal Rights of Enfusion Stockholders (see page 179)

Enfusion Stockholders who do not vote in favor of approval of the Merger Agreement Proposal, who continuously hold their shares of Enfusion
Common Stock or Enfusion Class B Common Stock through the Effective Time and who otherwise comply precisely with the applicable provisions of Section 262 of the DGCL will be entitled to seek appraisal of the fair value of their shares of
Enfusion Common Stock or Enfusion Class B Common Stock, as determined by the Delaware Court of Chancery, if the Merger is completed. The “fair value” of your shares of Enfusion Common Stock or Enfusion Class B Common Stock as
determined by the Delaware Court of Chancery could be greater than, the same as, or less than the value of the Merger Consideration that you would otherwise be entitled to receive under the terms of the Merger Agreement. Enfusion Stockholders who
wish to exercise the right to seek an appraisal of their shares must so advise Enfusion by